Safety and tolerability in IPF
MOST COMMON ADVERSE EVENTS
JASCAYD® had a favorable tolerability and safety profile1
JASCAYD® treatment does not require liver or lab monitoring2
ADVERSE EVENTS IN ≥10% OF JASCAYD® PATIENTS AND MORE OFTEN THAN PLACEBO1
Placebo +/- background AF | JASCAYD® 18 mg +/- | |
|---|---|---|
| Diarrhea | 18% | 42% |
| Upper respiratory tract infection | 11% | 14% |
| Weight decreased | 10% | 12% |
| Decreased appetite | 7% | 10% |
| Nausea | 7% | 9% |
| Fatigue | 6% | 8% |
| Headache | 6% | 7% |
| Back pain | 4% | 7% |
| Vomiting | 5% | 6% |
| Respiratory tract infection | 3% | 6% |
ADVERSE EVENTS IN ≥10% OF JASCAYD® PATIENTS AND MORE OFTEN THAN PLACEBO1
Placebo +/- background AF (n=393) | JASCAYD® 9 mg +/- background nintedanib (n=392) | |
|---|---|---|
| Diarrhea | 18% | 32% |
| Upper respiratory tract infection | 11% | 12% |
| Weight decreased | 10% | 11% |
| Decreased appetite | 7% | 10% |
| Nausea | 7% | 9% |
| Fatigue | 6% | 8% |
| Headache | 6% | 6% |
| Back pain | 4% | 6% |
| Vomiting | 5% | 5% |
| Respiratory tract infection | 3% | 4% |
DIARRHEA
Frequency of diarrhea varied across treatment groups in the trial2
The most frequent adverse event associated with JASCAYD® 18 mg was diarrhea, and in most cases it was mild to moderate in intensity and generally occurred within the first 3 months of treatment2
Only 1% of patients taking JASCAYD® 18 mg monotherapy discontinued treatment due to diarrhea events3
OTHER SAFETY AND TOLERABILITY CONSIDERATIONS
Safety and tolerability considerations when prescribing JASCAYD®2
Psychological disorders are common in PPF and IPF. While no imbalance was seen with JASCAYD® vs placebo in psychiatric events, routine monitoring is recommended2
Quicklinks
References
-
Data on file. Boehringer Ingelheim International GmbH. FIBRONEER-IPF CTR. 2025.
-
JASCAYD® UAE Local SmPC; May 2026.
-
Oldham JM, Azuma A, Kreuter M, et al. Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial. Am J Respir Crit Care Med. Published online February 21, 2026.
-
Oldham JM, Azuma A, Kreuter M, et al. Effect of nerandomilast on clinical outcomes in patients with idiopathic pulmonary fibrosis (IPF): data from final database lock of the FIBRONEER-IPF trial. Presented at: European Respiratory Society (ERS) International Congress; September 2025; Vienna, Austria. Poster available from: https://www.globalmedcomms.com/respiratory/ERS2025/Oldham1
MLR ID: PC-AE-102892
Expiry Date: 10/05/2028